| Literature DB >> 33082825 |
Junquan Liang1, Fengyi Wang2, Jiajia Huang1, Yunxiang Xu1, Guizhen Chen2.
Abstract
OBJECTIVE: This study aimed to appraise the efficacy and safety of the tonifying-Shen (kidney) principle (TS (TK) principle) for primary osteoporosis (POP).Entities:
Year: 2020 PMID: 33082825 PMCID: PMC7559232 DOI: 10.1155/2020/5687421
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The search strategy used in the PubMed database.
| Serial number | Search items |
|---|---|
| #1 | Bushen |
| #2 | Tonifying Shen |
| #3 | Bu Shen |
| #4 | Yishen |
| #5 | Nourishing the kidney |
| #6 | Tonifying the kidney |
| #7 | Yi Shen |
| #8 | Tonifying kidney |
| #9 | Nourishing kidney |
| #10 | Nourishing Shen |
| #11 | Reinforcing the kidney |
| #12 | Reinforcing kidney |
| #13 | Reinforcing Shen |
| #14 | Invigorating the kidney |
| #15 | Invigorating kidney |
| #16 | Invigorating Shen |
| #17 | Kidney-reinforcing |
| #18 | Kidney reinforcing |
| #19 | Shen reinforcing |
| #20 | Shen-reinforcing |
| #21 | Kidney-invigorating |
| #22 | Kidney invigorating |
| #23 | Shen-invigorating |
| #24 | Kidney-tonifying |
| #25 | Shen-tonifying |
| #26 | Kidney tonifying |
| #27 | Shen tonifying |
| #28 | Shen invigorating |
| #29 | Invigorating Shen |
| #30 | #1 or #2—#29 |
| #31 | Primary osteoporosis |
| #32 | Osteoporosis |
| #33 | Age-related osteoporosis |
| #34 | Age-related osteoporosis |
| #35 | Osteoporosis, senile |
| #36 | Osteoporosis, involutional |
| #37 | Senile osteoporosis |
| #38 | Osteoporosis, age-related |
| #39 | Osteoporosis, age-related |
| #40 | Bone loss, age-related |
| #41 | Age-related bone loss |
| #42 | Age-related bone losses |
| #43 | Bone loss, age-related |
| #44 | Bone losses, age-related |
| #45 | #31 or #32—#44 |
| #46 | Randomized controlled trials |
| #47 | Randomized |
| #48 | Randomly |
| #49 | Random |
| #50 | RCTs |
| #51 | #46 or #47—#50 |
| #52 | #30 and #45 and #51 |
Figure 1The flowchart of the selection procedure.
Characteristics of the included studies.
| No. | Included studies (author, year) | Age (years) | Participants (experimental group/control group) | Intervention | Outcomes | Adverse effects (experimental group/control) | Treatment periods (months) | Follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control group | Experimental group | Control group | Experimental group | Secondary outcomes | Primary outcomes | ||||||
| 1 | Zheng et al. [ | 63.9 ± 2.81 | 63.91 ± 2.86 | 70/70 | Placebo capsules ± calcium carbonate | Bushen Yijing Fang ± calcium carbonate | — | BMD of femoral neck; adverse effects | 9/8 | 36 | 120 |
| 2 | Liu and Wang [ | 56.15 ± 6.77 | 55.86 ± 6.92 | 62/62 | Alendronate sodium tablets ± calcium carbonate D3 tablets | Erxian Bushen decoction ± acupuncture and moxibustion ± alendronate sodium tablets ± calcium carbonate D3 tablets | — | Effectiveness rate; BMD of femoral neck and lumbar spine | — | 6 | — |
| 3 | Xu et al. [ | 63.90 ± 7.59 | 65.16 ± 6.82 | 32/31 | Calcium carbonate D3 | Thunder-fire moxibustion ± calcium carbonate D3 | VAS scores | — | — | 1 | 1 |
| 4 | Zhu et al. [ | 64.9 ± 6.0 | 65.4 ± 6.3 | 61/61 | Calcium carbonate ± vitamin D | Xian Ling Gu Bao capsules ± calcium carbonate ± vitamin D | — | BMD of femoral neck and lumbar spine; adverse effects | 11/11 | 12 | 12 |
| 5 | Zhao and Yan [ | 61.3 ± 4.1 | 62.1 ± 4.1 | 50/50 | Caltrate ± alpha D3 calciferol | Traditional Chinese medicine prescription ± caltrate ± alpha D3 calciferol | VAS scores | Effectiveness rate; BMD of lumbar spine (L2–4); adverse effects | 9/6 | 6 | 6 |
| 6 | Yuan et al. [ | — | — | 40/40 | Alendronate ± calcium carbonate D3 | Chinese herbal medicine ± alendronate ± calcium carbonate D3 | — | Effectiveness rate | — | 6 | — |
| 7 | Huang [ | 65.5 ± 1.6 | 65.7 ± 1.5 | 70/70 | Calcium carbonate D3 ± alfacalcidol soft capsules | Bushenhuoxuetang ± calcium carbonate D3 ± alfacalcidol soft capsules | VAS scores | Effectiveness rate | — | 2 | — |
| 8 | Wu et al. [ | 56.4 ± 4.6 | 55.6 ± 4.3 | 34/34 | Caltrate D600 | Xian Ling Gu Bao capsules ± caltrate D600 | — | BMD of femoral neck and lumbar spine | — | 12 | — |
| 9 | Liu et al. [ | 62.8 ± 5.9 | Liu 2011 (3) | A: 35/35; B: 35 | Calcichew D3 tablets | Liu 2011 (3) | VAS scores | Effectiveness rate; BMD of lumbar spine | — | 6 | — |
| 10 | Lu [ | 62.14 ± 6.34 | 60.84 ± 6.95 | 25/22 | Calcium carbonate D3 | Acupoint catgut embedding ± calcium carbonate D3 | — | Effectiveness rate | — | 6 | — |
| 11 | Han et al. [ | 67.39 ± 4. 05 | 67.42 ± 3. 89 | 30/30 | Caltrate | Shuganwenshentanyushuangjietang ± acupuncture and moxibustion ± caltrate | — | Effectiveness rate | — | 6 | — |
| 12 | Liu et al. [ | 62.8 ± 5.9 | Liu 2011 (1) | A: 35/35 B: 35 | Calcichew D3 tablets | Liu 2011 (1) | TCM symptom integral | — | 0/0/4 | 6 | — |
| 13 | Peng et al. [ | — | — | 35/35 | Calcichew D3 tablets ± alendronate sodium tablets | Acupoint catgut embedding ± calcichew D3 tablets ± alendronate sodium tablets | VAS scores | Effectiveness rate; BMD of lumbar spine | — | 3 | — |
| 14 | Peng et al. [ | — | — | 45/45 | Calcichew D3 tablets ± alendronate sodium tablets | Acupoint catgut embedding ± calcichew D3 tablets ± alendronate sodium tablets | VAS scores | Effectiveness rate; BMD of lumbar spine | — | 3 | 3 |
| 15 | Zhong et al. [ | — | — | 45/45 | Calcichew D3 tablets ± alendronate sodium tablets | Acupoint catgut embedding ± calcichew D3 tablets ± alendronate sodium tablets | VAS scores | Effectiveness rate; BMD of lumbar spine | — | 3 | — |
| 16 | Zou et al. [ | 66.73 ± 3.71 | 66.27 ± 3.18 | 60/60 | Caltrate D tablets ± alendronate sodium tablets ± calcitriol soft capsules | Acupoint injection ± caltrate D tablets ± alendronate sodium tablets ± calcitriol soft capsules | — | Effectiveness rate; BMD of femoral neck and lumbar spine; adverse effects | 0/0 | 6 | — |
| 17 | Ma and Fan [ | 68.43 ± 3.68 | 68.56 ± 3.79 | 42/42 | Calcium carbonate ± vitamin D tablets | Bushenzhuanggutang ± acupuncture and moxibustion ± calcium carbonate ± vitamin D tablets | — | Effectiveness rate | — | 3 | 12 |
| 18 | Lin [ | — | — | 24/22 | Osteoform capsules | Acupoint catgut embedding ± osteoform capsules | — | BMD of femoral neck | — | 6 | — |
| 19 | Lin [ | — | — | 20/18 | Osteoform capsules | Acupoint catgut embedding ± osteoform capsules | — | BMD of femoral neck | — | 6 | — |
| 20 | Qi [ | 75.42 ± 6.83 | 76.5 ± 7.28 | 100/100 | Caltrate D | Bushenqianggufang ± caltrate D | — | Effectiveness rate; BMD of femoral neck and lumbar spine | — | 3 | 3 |
| 21 | Li et al. [ | 75.4 ± 4.9 | 72.6 ± 5.5 | 30/30 | Calcitriol soft capsules ± caltrate D600 | Bushenjianpitang ± calcitriol soft capsules ± caltrate D600 | — | Effectiveness rate | — | 3 | — |
| 22 | Hu and Li [ | — | — | 155/145 | Caltrate D ± miacalcic | Shangkeyishenjianguwan ± caltrate D ± miacalcic | — | BMD of lumbar spine | — | 3 | 6 |
| 23 | Liu and Gong [ | 59.88 ± 7.46 | 60.49 ± 7.25 | 38/38 | Calcitriol soft capsules ± calcium carbonate D3 ± alendronate sodium tablets | Bushenjianpihuoxuefang ± calcitriol soft capsules ± calcium carbonate D3 ± alendronate sodium tablets | — | Effectiveness rate; BMD of femoral neck and lumbar spine; adverse effects | 6/4 | 6 | — |
| 24 | Chen et al. [ | 66.22 ± 11.3 | 65.12 ± 12.41 | 32/28 | Salmon calcitonin | Bushenjiangufang ± salmon calcitonin | VAS scores | Effectiveness rate | — | 6 | — |
| 25 | Zou [ | — | — | 31/31 | Alendronate sodium tablets ± calcichew D3 tablets | Bushenjiangutang ± alendronate sodium tablets ± calcichew D3 tablets | — | BMD of femoral neck and lumbar spine | — | 6 | — |
| 26 | Han [ | 55.32 ± 1.53 | 54.08 ± 3.26 | 28/28 | Alfacalcidol soft capsules ± caltrate | Bushenzhuanggutang ± alfacalcidol soft capsules ± caltrate | — | Effectiveness rate; adverse effects | 0/0 | 2 | — |
| 27 | Huang et al. [ | — | — | 88/88 | Alendronate sodium tablets | Bushentang ± alendronate sodium tablets | VAS scores | Effectiveness rate; BMD of femoral neck and lumbar spine; adverse effects | 0/0 | 6 | — |
| 28 | Huang et al. [ | /— | — | 46/46 | Salmon calcitonin | Bushenhuoxuefang ± salmon calcitonin | — | BMD of femoral neck and lumbar spine | — | 6 | — |
| 29 | Song et al. [ | 76.1 ± 3.78 | 76.4 ± 3.56 | 90/90 | Salmon calcitonin | Bushenhuoxuefang ± salmon calcitonin | — | Effectiveness rate; adverse effects | 0/0 | 12 | — |
| 30 | Pan and Ding [ | 57. 2 ± 11. 2 | 56. 9 ± 11. 0 | 43/43 | Oyster shell calcium capsules | Bushenhuoxuefang ± oyster shell calcium capsules | — | Effectiveness rate; BMD of femoral neck and lumbar spine; adverse effects | 0/4 | 3 | — |
| 31 | Wang [ | 62.25 ± 5.01 | 62.18 ± 4.58 | 100/100 | Calcium carbonate and vitamin D3 tablets | Bushenhuoxuetang ± calcium carbonate and vitamin D3 tablets | — | Effectiveness rate; BMD of lumbar spine | — | 3 | — |
| 32 | Gui et al. [ | 66.28 ± 8.17 | 66.19 ± 8.34 | 30/30 | Alendronate sodium tablets ± caltrate D | Bushenyiqihuayutang ± alendronate sodium tablets ± caltrate D | — | Effectiveness rate; BMD of total hip and lumbar spine; adverse effects | 4 Feb | 6 | — |
| 33 | Liu et al. [ | 59.8 ± 8.6 | Liu 2011 (2) | A: 45/45 B: 45 | Calcichew D3 tables | Liu 2011 (2) | TCM symptom integral; VAS scores | Effectiveness rate; BMD of lumbar spine | — | 6 | — |
| 34 | Ouyang et al. [ | 65.6 ± 6.6 | 64.4 ± 5.3 | 25/30 | Alendronate | Acupuncture and moxibustion ± alendronate | TCM symptom integral | BMD of lumbar spine and proximal femur | — | 6 | — |
| 35 | Zhou et al. [ | 55 ± 4 | 56 ± 4 | 30/30 | Salmon calcitonin | Acupoint injection | TCM symptom integral | BMD of lumbar spine | — | 2 | — |
| 36 | Xie et al. [ | 61.00 ± 3.12 | 59.40 ± 4.12 | 30/31 | Vitamin D chewable tablets ± calcitriol soft capsules | Gushenfang ± vitamin D chewable tablets ± calcitriol soft capsules | — | Effectiveness rate; adverse effects | 0/0 | 3 | — |
Notes: the experimental group of Liu 2011 (1) was divided into 2 groups, respectively: Liu 2011 (1) and Liu 2011 (1); the experimental group of Liu 2011 (2) was divided into 2 groups, respectively: Liu 2011 (2) and Liu 2011 (2); the experimental group of Liu 2011 (3) was divided into 2 groups, respectively: Liu 2011 (3) and Liu 2011 (3). A: experimental group; B: control group.
Brief table of risk assessment.
| Risk of bias assessment (yes/no/unclear) | |||||||
|---|---|---|---|---|---|---|---|
| No. | Included studies (first author, year) | Random sequence generation | Allocation concealment | Blinding of participants, personnel, and outcome assessors | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
| 1 | Zheng et al. [ | Randomization number table | Yes | Yes | Yes | No | No |
| 2 | Liu and Wang [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 3 | Xu et al. [ | Draw opaque envelope randomly | Yes | Yes | Yes | No | No |
| 4 | Zhu et al. [ | Using a computer random number generator | Yes | Yes | Yes | No | No |
| 5 | Zhao et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 6 | Yuan et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 7 | Huang [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 8 | Wu et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 9 | Liu et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 10 | Lu [ | Doll's clinical case random table | Unclear | Unclear | Yes | No | No |
| 11 | Han et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 12 | Liu et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 13 | Peng et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 14 | Peng et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 15 | Zhong et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 16 | Zou et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 17 | Ma et al. [ | Drawing of lots | Unclear | Unclear | Yes | No | No |
| 18 | Lin [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 19 | Lin [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 20 | Qi [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 21 | Li et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 22 | Hu and Li [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 23 | Liu and Gong [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 24 | Chen et al. [ | Coin tossing | Unclear | Unclear | Yes | No | No |
| 25 | Zou [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 26 | Han [ | Coin tossing | Unclear | Unclear | Yes | No | No |
| 27 | Huang et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 28 | Huang et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 29 | Song et al. [ | Draw lots randomly | Unclear | Unclear | Yes | No | No |
| 30 | Pan and Ding [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 31 | Wang [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 32 | Gui et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 33 | Liu et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 34 | Ouyang et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 35 | Zhou et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
| 36 | Xie et al. [ | Randomization number table | Unclear | Unclear | Yes | No | No |
Figure 2Risk of bias assessment. Notes: the experimental group of Liu 2011 (1) was divided into 2 groups, respectively: Liu 2011 (1) and Liu 2011 (1); the experimental group of Liu 2011 (2) was divided into 2 groups, respectively: Liu 2011 (2) and Liu 2011 (2); the experimental group of Liu 2011 (3) was divided into 2 groups, respectively: Liu 2011 (3) and Liu 2011 (3).
Figure 3(a) Effectiveness rates of different treatment methods included in the TS (TK) principle. (b) Effectiveness rates of different specific therapies included in TCM herbal medicine. (c) Effectiveness rates of different treatment periods. (d) BMD (lumbar spine) of different treatment periods. (e) BMD (proximal femur (femoral neck or total hip)) of different treatment periods. (f) Adverse effects. (g) TCM symptom integral. (h) VAS scores. Notes: the experimental group of Liu 2011 (2) was divided into 2 groups, respectively: Liu 2011 (2) and Liu 2011 (2); the experimental group of Liu 2011 (3) was divided into 2 groups, respectively: Liu 2011 (3) and Liu 2011 (3).
Figure 4Funnel plot of effectiveness rates of different treatment methods included in the TS (TK) principle.
Figure 5GRADE evidence profile.